Pharmaceutical intelligence for Hangzhou Sumgen Biotech with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalAugust 12, 2026

Phase 1a/1b trial of SG301 for relapsed/refractory multiple myeloma initiated by Hangzhou Sumgen Biotech

Hangzhou Sumgen Biotech has initiated Phase 1a/1b clinical trial to evaluate SG301 in patients with relapsed or refractory multiple myeloma and other hematological malignancies.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalAugust 12, 2026

Phase 1a/1b trial of SG301 for relapsed/refractory multiple myeloma initiated by Hangzhou Sumgen Biotech

Hangzhou Sumgen Biotech has initiated Phase 1a/1b clinical trial to evaluate SG301 in patients with relapsed or refractory multiple myeloma and other hematological malignancies.

Competitive activity

No signals indexed for this entity yet.

Assets

SG301 →

Therapeutic areas

Hematology →

Multiple Myeloma →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.